

**Department of  
Pharmacology and Toxicology**



**2000**

**Annual Report**



**Department of Pharmacology and Toxicology**

## TABLE OF CONTENTS

<b>CHAIRMAN'S SUMMARY</b>	<b>1</b>
<b>MISSION STATEMENT</b>	<b>3</b>
<b>FACULTY/RESEARCH DESCRIPTIONS</b>	<b>4</b>
<b>PERSONNEL</b>	<b>10</b>
<b>PUBLICATIONS (SALARIED FACULTY AND STAFF)</b>	<b>15</b>
<b>ABSTRACTS (SALARIED FACULTY AND STAFF)</b>	<b>21</b>
<b>INVITED SCIENTIFIC PRESENTATIONS AND SEMINARS</b>	<b>30</b>
<b>RESEARCH GRANTS AND CONTRACTS</b>	<b>35</b>
<b>TEACHING</b>	<b>46</b>
<b>SERVICE</b>	<b>47</b>
<b>HONORS AND AWARDS</b>	<b>47</b>
<b>STANDING COMMITTEES</b>	<b>48</b>
<b>INDIVIDUAL FACULTY REPORTS</b>	
<b>Frederick W. Benz</b>	<b>49</b>
<b>Laurence A. Carr</b>	<b>54</b>
<b>Theresa S. Chen</b>	<b>57</b>
<b>Paul N. Epstein</b>	<b>61</b>
<b>David Gozal</b>	<b>64</b>
<b>Evelyne Gozal</b>	<b>71</b>
<b>David W. Hein</b>	<b>75</b>
<b>Harrell E. Hurst</b>	<b>85</b>
<b>Y. James Kang</b>	<b>91</b>
<b>W. Glenn McGregor</b>	<b>98</b>
<b>Steven R. Myers</b>	<b>101</b>
<b>Donald E. Nerland</b>	<b>111</b>
<b>William M. Pierce, Jr.</b>	<b>115</b>
<b>Peter P. Rowell</b>	<b>121</b>
<b>Zhao-hui (Joe) Song</b>	<b>125</b>
<b>J. Christopher States</b>	<b>129</b>
<b>Leonard C. Waite</b>	<b>133</b>
<b>Walter M. Williams</b>	<b>138</b>


## **I. Chairman's Summary**

The first year of the new millennium will be remembered as a year of substantially increased efforts and development in graduate education, both within the Department and within the University as a whole. A major objective of the University of Louisville's Challenge for Excellence includes a shift in emphasis from high access undergraduate studies to more focussed efforts in research scholarship and graduate education. All graduate programs in the School of Medicine were asked to set ambitious enrollment management plans requiring substantial growth in the number of graduate students. Under the leadership of Dr. William Pierce, the new Director of our graduate program, the Department held a major retreat focusing on graduate education in January. As part of the strategic plans formulated at that retreat, the Department accelerated its efforts to form partnerships with faculty in clinical departments and institutes. The Center for Genetics and Molecular Medicine continues to be administratively located within the Department. Six new faculty with appointments in the James Graham Brown Cancer Center (**John W. Eaton, PhD, W. Glenn McGregor, MD, Donald M. Miller, MD, PhD, and Wolfgang Zacharias, PhD**), the Kosair Children's Research Institute (**Paul N. Epstein, PhD**), and the Birth Defects Center (**M. Michele Pisano, PhD**) were added to the Department of Pharmacology and Toxicology over the year. The new faculty brought exceptional research expertise and opportunities for the students in the Department graduate program. Their specific research interests are described in the Faculty/Research Descriptions (pages 3-8).


Other implementations of the strategic plan included curricular revisions in the PhD program, and the identification of two pathways for the MS program; a laboratory research track and an academic research track. Intensified recruitment efforts led to the addition of eight new students into the graduate program. Another important strategy was completion of a Department Conference Room suitable for graduate student seminars and committee meetings. Much of the year was spent in renovation of a new Peter K. Knoefel Conference Room located near the Department office. Thanks to the efforts of many individuals within the Department and Physical Plant, the state-of-the-art Peter K. Knoefel Conference Room hosted the First Annual William J. Waddell Seminar in January 2001.

The University of Louisville conducted a major reallocation over the year. This strategy benefited the Department through enhanced faculty, staff, and graduate student salaries. The School of Medicine initiated a common recruitment gateway for graduate students, named Integrated Programs in the Biomedical Sciences (IPIBS). In other notable events, Chris States and Glenn McGregor of our Department hosted a successful Midwest DNA Repair Conference in May. One of our most distinguished alumni, Dr. Ray Woosley, Professor and Chairman of the Department of Pharmacology at Georgetown University School of Medicine presented the second annual KC Huang Memorial Seminar in November. Dr. Bruce Temple from Harvard University School of Public Health presented his work as the Burroughs Wellcome Visiting Professor in the Basic Medical Sciences. Dr. Woosley's seminar was in collaboration with the Center for Genetics and Molecular Medicine; Dr. Temple's seminar was in collaboration with the Department of Biochemistry and Molecular Biology.

**Department of Pharmacology and Toxicology  
Publications**



**Department of Pharmacology and Toxicology  
Abstracts**



As this report delineates, faculty, staff, students, publications, and research funding were all increased substantially this year. The Department of Pharmacology and Toxicology continues to grow through implementation of our strategic plan to achieve the University of Louisville's Challenge for Excellence.

Sincerely,

David W. Hein, Ph.D.  
Peter K. Knoefel Professor and Chairman

## **II. Mission Statement**

The Department of Pharmacology and Toxicology is committed to academic excellence and to the attainment of regional, national, and international recognition for the quality of its educational, research, and service activities. Guided by the University of Louisville Challenge for Excellence to become a preeminent metropolitan research university, the Department Strategic Plan will focus on accomplishment of five broad objectives:

- Provide instruction in pharmacology and toxicology of the highest quality for the education and preparation of medical, dental, nursing, and other health care professional students. Emphasis will be placed on the fundamental principles necessary for life-long learning and the essential knowledge required for rational, effective, and safe use of drug therapy.
- Advance biomedical knowledge through active contribution to high quality research and other scholarly activities, particularly in pharmacology and toxicology and other areas of focus within the University of Louisville Challenge for Excellence.
- Provide high quality research and educational experiences in pharmacology and toxicology for the education and training of future biomedical scientists who can provide and advance biomedical education, research, and service.
- Provide instruction of the highest quality in pharmacology and toxicology that is appropriate for students at the undergraduate, graduate, and postgraduate levels.
- Provide high quality service to the School of Medicine, the Health Sciences Center, the University, the people of Louisville and the surrounding region, the Commonwealth of Kentucky, professional organizations, the nation, and the world.

### III. Faculty/Research Descriptions (Primary and joint appointments)



**George R. Aronoff, M.D. (Indiana University)**  
**Professor**

Effects of uremia on drug disposition in humans; drug nephrotoxicity and renal drug metabolism, artificial intelligence.

---



**Frederick W. Benz, Ph.D. (University of Iowa)**  
**Professor**

Biochemical pharmacology and toxicology; biochemical mechanisms of drug action and toxicity.

---



**Laurence A. Carr, Ph.D. (Michigan State University)**  
**Professor**

Biochemical neuropharmacology; functional role of brain biogenic amines; interaction of brain neurotransmitters with peripheral immune system.

---



**Theresa S. Chen, Ph.D. (University of Louisville)**  
**Professor**

Biochemical toxicology; role of glutathione in aging toxicology; general and specific toxicity of environmental pollutants.

---



**Nicholas A. Delamere, Ph.D. (University of East Anglia)**  
**Professor**

Electrolyte transport mechanisms in epithelia; second messenger regulation of aqueous humor secretion processes; the role of ion transport mechanisms in preserving transparency of the ocular lens.

---



**John W. Eaton, Ph.D. (University of Michigan)**  
**Professor**

Biomaterial-mediated inflammation and fibrosis; sub-endothelial glycochelates, transition metals and diabetic neuropathy; cellular and molecular basis of iron toxicity

---



**Paul N. Epstein, Ph.D. (Baylor College of Medicine)**  
**Professor**  
**Carol B. McFerran Endowed Chair in Pediatric Diabetes Research**

Development of transgenic models for the study of causes and complications of diabetes, and the production of mice that are more resistant to diabetes by introducing genes to protect from oxidative stress.

---



**David Gozal, M.D. (Hebrew University of Jerusalem)**  
**Professor**  
**Children's Hospital Foundation Pediatric Research Chair**

Signal transduction mechanisms underlying ventilatory response to hypoxia; neuronal adaptations to intermittent hypoxia: growth factors, intracellular signaling, and genomic implications.

---



**Evelyne Gozal, Ph.D. (University of Southern California)**  
**Assistant Professor**

Signal transduction pathways involved in neuronal cell survival and neuronal cell death during hypoxia; cellular mechanisms underlying brain adaptation to chronic and intermittent hypoxia; identification of the kinases and transcription factors activated by hypoxia, leading to gene induction and to adaptation to oxygen deprivation.

---





**David W. Hein, Ph.D. (University of Michigan)**  
**Peter K. Knoefel Professor and Chairman**

Molecular pharmacogenetics and epidemiology. Genetic predisposition to cancer and drug toxicity.


---



**Harrell E. Hurst, Ph.D. (University of Kentucky)**  
**Professor**

Analytical toxicology and kinetics with emphasis on qualitative and quantitative techniques, including gas chromatography, high pressure liquid chromatography and GC/mass spectrometry.


---



**Y. James Kang, Ph.D. (Iowa State University)**  
**Associate Professor**

Molecular and cardiac toxicology. Transgenic and knock-out animal models to study oxidative injury and antioxidant systems in the heart. Biological functions and toxicological significance of metallothionein and glutathione in vivo.

---



**W. Glenn McGregor, M.D. (University of Michigan)**  
**Associate Professor**

Molecular biology of DNA damage, repair and mutagenesis; molecular mechanisms of mutagenesis induced by model carcinogens; molecular mechanisms of replication of DNA templates containing well-defined site specific damage.

---



**Donald M. Miller, M.D., Ph.D. (Duke University)**  
**Professor**  
**James Graham Brown Foundation Chair**

Molecular and clinical oncology; modulation of oncogene expression; triplex DNA based gene therapy; treatment of melanoma.

---



**Frederick N. Miller, Ph.D. (University of Cincinnati)**  
**Professor**

Macromolecular permeability in the microcirculation.

---



**Steven R. Myers, Ph.D. (University of Kentucky)**  
**Associate Professor**

Drug metabolism, metabolism of xenobiotics and chemical carcinogens; use of hemoglobin as biomarker in exposure to xenobiotics.

---



**Donald E. Nerland, Ph.D. (University of Kansas)**  
**Professor**

Biochemical toxicology; metabolism of drugs and environmental pollutants.

---



**William M. Pierce, Jr., Ph.D. (University of Louisville)**  
**Professor**

Drug design and organ targeting strategies; novel drugs for treatment of osteoporosis; mechanisms of bone formation and resorption; proteomic analysis and study of structure and function of biomolecules and xenobiotics using mass spectrometry.

---



**M. Michele Pisano, Ph.D. (Thomas Jefferson University)**  
**Associate Professor**

Molecular development toxicology; gene-environment interactions in normal and abnormal embryonic development; growth factor directed cellular signal transduction in embryonic cell growth and differentiation.

---



**George C. Rodgers, Jr. M.D., Ph.D. (Yale University, Ph.D.;  
State University of New York, M.D.)  
Professor**

Toxicokinetics in drug overdoses and pharmacokinetics in pediatric disease states.

---



**Peter P. Rowell, Ph.D. (University of Florida)  
Professor**

Neuropharmacology; effect of drugs on brain neurotransmitters and receptors.

---



**Zhao-Hui (Joe) Song, Ph.D. (University of Minnesota)  
Assistant Professor**

Molecular pharmacology; cloning and functional characterization of novel G protein-coupled receptors; molecular mechanisms of action and structure-function relationships of cannabinoid (marijuana) receptors.

---



**J. Christopher States, Ph.D. (Albany Medical College)  
Associate Professor**

Molecular biology and molecular genetics of DNA damage and repair in humans

---



**Janice E. Sullivan, M.D. (University of Minnesota)  
Assistant Professor**

Clinical pharmacology with a focus on developmental pharmacokinetics and pharmacodynamics.

---



**Leonard C. Waite, Ph.D. (University of Missouri)  
Professor**

Endocrine pharmacology; mechanism of action of hormones; pharmacological modulation of hormone action; mineral homeostasis.

---



**Walter M. Williams, M.D., Ph.D. (University of Louisville)  
Professor**

Studies of drug elimination (metabolism and excretion).

---



**John L. Wong, Ph.D. (University of California-Berkeley)  
Professor**

Biological chemistry; molecular dosimetry in environmental health; preparation of monoclonal antibodies in biomarker studies.

---



**Wolfgang Zacharias, Ph.D. (Philipps-University Marburg)  
Associate Professor**

Ribozymes for gene therapy in rheumatoid arthritis; involvement and roles of cathepsins in oral cancers; gene expression profiling with DNA microarray chip technology

---



**Thom J. Zimmerman, M.D., Ph.D. (University of Illinois, M.D.;  
University of Florida, Ph.D.)  
Professor**

Pharmacology of drugs used to treat glaucoma; carbonic anhydrase inhibitors, cholinergic and adrenergic agents.

---

## **IV. Personnel**

### **Faculty with Primary Appointments**

**Benz, Frederick W.**, Professor; Ph.D., Pharmacology, University of Iowa (1970).

**Carr, Laurence A.**, Professor; Ph.D., Pharmacology, Michigan State University (1969).

**Chen, Theresa S.**, Professor; Ph.D., Pharmacology, University of Louisville (1971).

**Hein, David W.**, Peter K. Knoefel Professor and Chair; Ph.D., Pharmacology, University of Michigan (1982).

**Hurst, Harrell E.**, Professor; Ph.D., Toxicology, University of Kentucky (1978).

**McGregor, W. Glenn**, Associate Professor; M.D., University of Michigan (1976).

**Myers, Steven R.**, Associate Professor; Ph.D., Pharmacology, University of Kentucky (1986).

**Nerland, Donald E.**, Professor; Ph.D., Medicinal Chemistry, University of Kansas (1974).

**Pierce, William M., Jr.**, Professor and Graduate Program Director; Ph.D., Pharmacology and Toxicology, University of Louisville (1981).

**Rowell, Peter P.**, Professor; Ph.D., Pharmacology and Therapeutics, University of Florida (1975).

**Song, Zhao-Hui (Joe)**, Assistant Professor; Ph.D., Pharmacology, University of Minnesota (1992).

**States, J. Christopher**, Associate Professor; Ph.D., Molecular Biology and Pathology, Albany Medical College/Union University (1980).

**Waite, Leonard C.**, Professor and Vice Chairman; Ph.D., Pharmacology, University of Missouri (1969).

**Williams, Walter M.**, Professor; Ph.D., Pharmacology, University of Louisville (1970); M.D., University of Louisville (1974).

### **Faculty with Joint Appointments**

**Aronoff, George R.**, Professor of Medicine, and Pharmacology and Toxicology; M.D., Indiana University (1975).

**Delamere, Nicholas A.**, Professor of Ophthalmology and Visual Sciences, and Pharmacology and Toxicology; Ph.D., Membrane Physiology and Biophysics, University of East Anglia, Norwich, England (1976).

**Eaton, John W.**, James Graham Brown Professor of Cancer Biology, Department of Medicine, and Professor of Pharmacology and Toxicology; Ph.D., Biological Anthropology and Human Genetics, University of Michigan (1969).

**Epstein, Paul N.\*** Carol B. McFerran Chair in Pediatric Diabetes Research and Professor of Pediatrics, and Pharmacology and Toxicology; Ph.D., Pharmacology, Baylor College of Medicine (1981).

**Gozal, David\*** Children's hospital Foundation Pediatric Research Chair, Professor of Pediatrics, and Pharmacology and Toxicology; M.D., Hebrew University of Jerusalem, Hadassah Medical School (1979).

**Gozal, Evelyne\*** Assistant Professor of Pediatrics, and Pharmacology and Toxicology; Ph.D., Toxicology, University of Southern California (1997).

**Kang, Y. James\*** Associate Professor of Medicine, and Pharmacology and Toxicology; Ph.D., Cell Biology and Zoology, Iowa State University (1989).

**Miller, Donald M.**, James Graham Brown Professor of Oncology, and Professor of Pharmacology and Toxicology; M.D., Duke University (1973); Ph.D., Biochemistry, Duke University (1973).

**Miller, Frederick N.**, Professor of Physiology and Biophysics, and Pharmacology and Toxicology; Ph.D., Pharmacology, University of Cincinnati (1971).

**Pisano, M. Michele**, Associate Professor of Molecular, Cellular and Craniofacial Biology; Ph.D., Anatomy, Thomas Jefferson University (1985).

**Rodgers, George C., Jr.**, Professor of Pediatrics, and Pharmacology and Toxicology; Ph.D., Organic Chemistry, Yale University (1964); M.D., State University of New York (1975).

**Sullivan, Janice E.**, Assistant Professor of Pediatrics, and Pharmacology and Toxicology; M.D., University of Minnesota (1988).

**Wong, John L.**, Professor of Chemistry, and Pharmacology and Toxicology; Ph.D., Chemistry, University of California at Berkeley (1966).

**Zacharias, Wolfgang**, Associate Professor of Medicine (Oncology), and Pharmacology and Toxicology; Ph.D., Biochemistry, Philipps-University, Marburg, Germany (1980).

\* Partial salary from Department of Pharmacology and Toxicology

**Zimmerman, Thom J.**, Professor of Ophthalmology and Visual Sciences, and Pharmacology and Toxicology; Ph.D., Pharmacology, University of Florida (1976); M.D., University of Illinois (1968). [Emeritus appointment January 1, 2001.]

### **Faculty with Associate Appointments**

**Bhatnagar, Aruni**, Professor of Medicine; Ph.D., Chemistry, University of Kanpur, India (1986).

**Brier, Michael E.**, Associate Professor of Medicine; Ph.D., Industrial and Physical Pharmacy, Purdue University (1986).

**Edmonds, Harvey L.**, Professor of Anesthesiology; Ph.D., Pharmacology, University of California at Davis (1974).

**Jumblatt, James E.**, Professor of Ophthalmology and Visual Sciences; Ph.D., Biological Sciences, Columbia University (1975).

**Lang, Calvin A.**, Professor of Biochemistry and Molecular Biology; Sc.D., Biochemistry and Nutrition, Johns Hopkins University (1954). [Retired June 30, 2000.]

**Rigor, Benjamin**, Professor of Anesthesiology; M.D., University of the East Ramon Magsaysay Memorial Medical Center (1962).

**Ross, Mitchell P.**, Associate Professor of Pediatrics; M.D., Oregon Health Sciences University (1985). [Resigned May 16, 2000.]

**Schurr, Avital**, Professor of Anesthesiology; Ph.D., Biochemical Pharmacology, Ben Gurion University, Beer Sheva, Israel (1977).

### **Faculty with Emeritus Appointments**

**Dagirmanjian, Rose**, Professor Emerita; Ph.D., University of Rochester (1960).

**Darby, Thomas D.**, Adjunct Professor Emeritus; Ph.D., Medical College of South Carolina (1957).

**Jarboe, Charles H.**, Professor Emeritus; Ph.D., University of Louisville (1956).

**Scharff, Thomas G.**, Professor Emeritus; Ph.D., University of Rochester (1956).

**Waddell, William J.**, Professor and Chair Emeritus; M.D., University of North Carolina (1955).

## **Faculty with Adjunct Appointments**

**Epstein, Paul N.**, Adjunct Associate Professor of Pharmacology and Toxicology; Ph.D., Baylor College of Medicine (1981).

**Friedman, Marvin A.**, Adjunct Professor of Pharmacology and Toxicology; Ph.D., Massachusetts Institute of Technology (1967).

**Gruber, Scott A.**, Adjunct Associate Professor of Pharmacology and Toxicology; M.D., SUNY Downstate Medical School (1983); Ph.D., University of Minnesota (1991).

**Hayes, A. Wallace**, Adjunct Professor of Pharmacology and Toxicology; Ph.D., Auburn University (1967).

**Holthouser, Michael G.**, Adjunct Assistant Professor of Pharmacology and Toxicology; M.D., University of Kentucky (1971).

**Horowitz, Stuart**, Adjunct Assistant Professor of Pharmacology and Toxicology; Ph.D., University of Rochester (1986).

**Lewis, Richard**, Adjunct Assistant Professor of Pharmacology and Toxicology; M.D., Case Western Reserve University (1980).

**Matyunas, Nancy**, Adjunct Instructor of Pharmacology and Toxicology; Pharm.D., University of Utah (1983).

**Nicholson, John A.**, Adjunct Assistant Professor of Pharmacology and Toxicology; D.M.D., University of Louisville (1979); Ph.D., University of Louisville (1968).

**Wedlund, Peter A.**, Adjunct Associate Professor of Pharmacology and Toxicology; Ph.D., Pharmaceutical Sciences, University of Washington (1981).

## **New Faculty Appointments**

**Eaton, John W.**, Ph.D., Professor, effective December 1, 2000.

**Epstein, Paul N.**, Ph.D., Professor, effective December 15, 2000.

**McGregor, W Glenn**, M.D., Associate Professor, effective February 1, 2000.

**Miller, Donald M.**, M.D., Ph.D., Professor, effective July 1, 2000.

**Pisano, M. Michele**, Ph.D., Associate Professor, effective August 1, 2000.

**Zacharias, Wolfgang**, Ph.D., Associate Professor, effective October 1, 2000.

## **Staff**

**Beauerle, Brian**, Research Technologist I

**Burke, Tom**, Research Technologist II



**Cai, Jian**, Technical Director, Mass Spectrometry Lab  
**Carpenter, Sharon**; Executive Secretary  
**Doll, Mark**; Research Associate  
**Greca, Edie**; Business Manager III  
**Hein, Joshua**, Student Assistant  
**Lewis, Stephanie**; Lab Research Technician III  
**Logsdon, Paula**, Student Assistant  
**McNeely, Sam**, Research Technologist II  
**Nosjean, Jeremy**; Student Assistant  
**Riddell, Amy**, Student Assistant  
**Rutledge, Rachel**; Student Assistant  
**Rubin-Teitel, Heddy**; Program Assistant III  
**Smith, Aaron**, Student Assistant  
**Smith, Leo**, Student Assistant  
**Smith, Ned**; Senior Research Technologist  
**Tucker, Alison**, Lab/Research Technician III  
**Tucker, Lindsay**, Lab/Research Technician III  
**Volk, Kelly**; Lab Research Technician III  
**Xiao, Gong H.**, Research Associate

## **Graduate Students**

### **Doctoral Program**

Brewer, Bradley G.  
 Campian, Cristian  
 Chen, Hainan  
 Clark, Denise  
 Elsherif, Laila  
 Fretland, Adrian  
 Fu, Xin  
 Hartford, April  
 Hou, Yining  
 Jacobs, Al (Chip)

Lambert, Jason  
 Li, Jian  
 Li, Nina  
 Nangju, Norma  
 Neale, Jason  
 Payne, Scot  
 Porter, Paul  
 Shen, Clare  
 Sun, Xichun  
 Zhu, Yuanqi

### **Masters Program**

Hennion, John  
 Khaled, Hana  
 Modi, Tanvi

## **Postdoctoral Fellows**

Cai, Jian  
 Feng, Wenke  
 Jiang, Guo-hui  
 Meng, Xianweng  
 Stefan, Mihaela  
 Wang, Guang-wu  
 Wang, Ju-Feng

Wu, Huiyun  
 Webster, Rose  
 Zhou, Zhan-Xiang  
 Zhao, Shuang  
 Zhong, Li-Chun  
 Zhong, Miao  
 Zhou, Dan

## **New Graduate Student Appointments**

Chen, Hainan  
Clark, Denise  
Khaled, Hana  
Li, Jian  
Li, Nina  
Modi, Tanvi  
Shen, Clare  
Zhu, Yuanqi

## **Graduations**

**Fretland, Adrian**, Ph.D. (awarded May 2000). Advisor: David W. Hein, Ph.D. Dissertation title: Pharmacogenetics of heterocyclic amine carcinogenesis.

**Hartford, April**, M.S. (awarded December 2000). Advisor: Nicholas Delamere, Ph.D. Thesis title: Calcium signaling in astrocytes of the optic nerve head; Evidence for a role for NA,K-ATPase Alpha-2.

**Neale, Jason**, M.S. (awarded December 2000). Advisor: William M. Pierce Jr., Ph.D. A novel bone selective estrogen: A candidate compound for the treatment of osteopenia.

## V. Publications (salaried faculty and staff)

### Papers

1. Alea OA, Czapla MA, Lasky JA, Simakajornboon N, Gozal E, and Gozal D (2000) PDGF- $\beta$  receptor expression and ventilatory acclimatization to hypoxia in the rat. *Am.J.Physiol Regul.Integr.Comp Physiol* **279**:R1625-R1633.
2. Bandla HP and Gozal D (2000) Dynamic changes in EEG spectra during obstructive apnea in children. *Pediatr.Pulmonol.* **29**:359-365.
3. Ben Ari J, Gozal D, Dorio RJ, Bowman CM, Reiff A, and Walker SM (2000) Superantigens and cystic fibrosis: resistance of presenting cells to dexamethasone. *Clin.Diagn.Lab Immunol.* **7**:553-556.
4. Cai L, Klein JB, and Kang YJ (2000) Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. *J.Biol.Chem.* **275**:38957-38960.
5. Chen TS, Richie JP, Nagasawa HT, and Lang CA (2000) Glutathione monoethyl ester protects against glutathione deficiencies due to aging and acetaminophen in mice. *Mech.Ageing Dev.* **120**:127-139.
6. Czapla MA, Gozal D, Alea OA, Beckerman RC, and Zadina JE (2000) Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine. *Am.J.Respir.Crit Care Med.* **162**:994-999.
7. Deitz AC, Zheng W, Leff MA, Gross M, Wen WQ, Doll MA, Xiao GH, Folsom AR, and Hein DW (2000) N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. *Cancer Epidemiol.Biomarkers Prev.* **9**:905-910.
8. Donny EC, Caggiula AR, Rowell PP, Gharib MA, Maldovan V, Booth S, Mielke MM, Hoffman A, and McCallum S (2000) Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. *Psychopharmacology (Berl)* **151**:392-405.
9. El Mallakh RS, Schurr A, Payne RS, and Li R (2000) Ouabain induction of cycling of multiple spike responses in hippocampal slices is delayed by lithium. *J.Psychiatr.Res.* **34**:115-120.
10. Feltzer RE, Gray RD, Dean WL, and Pierce WM (2000) Alkaline proteinase inhibitor of *Pseudomonas aeruginosa*. Interaction of native and N-terminally truncated inhibitor proteins with *Pseudomonas* metalloproteinases. *J.Biol.Chem.* **275**:21002-21009.
11. Ferreira AM, Clemente V, Gozal D, Gomes A, Pissarra C, Cesar H, Coelho I, Silva CF, and Azevedo MH (2000) Snoring in Portuguese primary school children. *Pediatrics* **106**:E64.

12. Gibbs PE, Wang XD, Li Z, McManus TP, McGregor WG, Lawrence CW, and Maher VM (2000) The function of the human homolog of *Saccharomyces cerevisiae* REV1 is required for mutagenesis induced by UV light. *Proc.Natl.Acad.Sci.U.S.A* **97**:4186-4191.
13. Gozal D and Simakajornboon N (2000) Passive motion of the extremities modifies alveolar ventilation during sleep in patients with congenital central hypoventilation syndrome. *Am.J.Respir.Crit Care Med.* **162**:1747-1751.
14. Gozal D, Gozal E, and Simakajornboon N (2000) Signaling pathways of the acute hypoxic ventilatory response in the nucleus tractus solitarius. *Respir.Physiol* **121**:209-221.
15. Gozal D (2000) Pulmonary manifestations of neuromuscular disease with special reference to Duchenne muscular dystrophy and spinal muscular atrophy. *Pediatr.Pulmonol.* **29**:141-150.
16. Gozal D, Simakajornboon N, Czapla MA, Xue YD, Gozal E, Vlastic V, Lasky JA, and Liu JY (2000) Brainstem activation of platelet-derived growth factor-beta receptor modulates the late phase of the hypoxic ventilatory response. *J.Neurochem.* **74**:310-319.
17. Gozal D, Simakajornboon N, Czapla MA, Xue YD, Gozal E, Vlastic V, Lasky JA, and Liu JY (2000) Platelet-derived growth factor  $\beta$  receptor activation modulates components of the hypoxic ventilatory response. *J.Neurochem.* **74**:310-319.
18. Gozal D (2000) Non-invasive ventilatory support in children. *J.Respir.Dis.for Pediatrician* **2**:47-53.
19. Gozal D (2000) Sleep disorders in children: A new and evolving discipline. *Louisville Med.* **47**:455-456.
20. Gozal D (2000) Obstructive sleep apnea in children.I.Pathophysiology. *Louisville Med.* **47**:457-459.
21. Gozal D (2000) Obstructive sleep apnea in children.II.Clinical diagnosis and associated morbidity. *Louisville Med.* **47**:533-535.
22. Gozal D (2000) Obstructive sleep apnea in children.III.Diagnosis and approach to treatment. *Louisville Med.* **47**:587-591.
23. Gozal D (2000) Obstructive sleep apnea in children. *Minerva Pediatrica* **52**:629-639.
24. Gozal D (2000) New insights into maturation of central components in cardiovascular and respiratory control, in *Sleep and Breathing in Children - A Developmental Approach* (Loughlin GM, Marcus CL, and Carrol JL eds) pp 207-229, Marcel Dekker, Inc., New York.
25. Han S, Rowell PP, and Carr LA (1999) D2 autoreceptors are not involved in the down-regulation of the striatal dopamine transporter caused by alpha-methyl-p-tyrosine. *Res.Commun.Molecul.Pathol.P.* **104**:331-338.

26. Hein DW, McQueen CA, Grant DM, Goodfellow GH, Kadlubar FF, and Weber WW (2000) Pharmacogenetics of the arylamine N-acetyltransferases: A symposium in honor of Wendell W. Weber. *Drug Metab Dispos.* **28**:1425-1432.
27. Hein DW, Grant DM, and Sim E (2000) Update on consensus arylamine N-acetyltransferase gene nomenclature. *Pharmacogenetics* **10**:291-292.
28. Hein DW (2000) N-Acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. *Toxicol.Lett.* **112-113**:349-356.
29. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, and Feng Y (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. *Cancer Epidemiol.Biomarkers Prev.* **9**:29-42.
30. Hou Y and Delamere NA (2000) Studies on H(+)-ATPase in cultured rabbit nonpigmented ciliary epithelium. *J.Membr.Biol.* **173**:67-72.
31. Kang YJ, Zhou ZX, Wu H, Wang GW, Saari JT, and Klein JB (2000) Metallothionein inhibits myocardial apoptosis in copper-deficient mice: role of atrial natriuretic peptide. *Lab Invest* **80**:745-757.
32. Kang YJ, Zhou ZX, Wang GW, Buridi A, and Klein JB (2000) Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. *J.Biol.Chem.* **275**:13690-13698.
33. Kang YJ, Wu H, and Saari JT (2000) Alterations in hypertrophic gene expression by dietary copper restriction in mouse heart. *Proc.Soc.Exp.Biol.Med.* **223**:282-287.
34. Kirk VG, Morielli A, Gozal D, Marcus CL, Waters KA, D'Andrea LA, Rosen CL, Deray MJ, and Brouillette RT (2000) Treatment of sleep-disordered breathing in children with myelomeningocele. *Pediatr.Pulmonol.* **30**:445-452.
35. Kreisman NR, Soliman S, and Gozal D (2000) Regional differences in hypoxic depolarization and swelling in hippocampal slices. *J.Neurophysiol.* **83**:1031-1038.
36. Li J, Yen TY, Allende ML, Joshi RK, Cai J, Pierce WM, Jaskiewicz E, Darling DS, Macher BA, and Young WW (2000) Disulfide bonds of GM2 synthase homodimers. Antiparallel orientation of the catalytic domains. *J.Biol.Chem.* **275**:41476-41486.
37. McCabe MJ, Singh KP, Reddy SA, Chelladurai B, Pounds JG, Reiners JJ, and States JC (2000) Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase. *J.Pharmacol.Exp.Ther.* **295**:724-733.
38. Myers SR, Spinnato JA, and Pinorini-Godly MT (2000) Tobacco smoke hemoglobin adducts in maternal and fetal blood. *Polycyclic Aromatic Compounds* **21**:151-166.

39. Myers SR and Pinorini MT (2000) Hemoglobin adducts of benzo(a)pyrene in tobacco smokers: Characterization of benzo[a]pyrene adducts in maternal and fetal blood samples. *Polycyclic Aromatic Compounds* **21**:167-186.
40. Myers SR and Pinorini-Godly MT (2000) Characterization of hemoglobin adducts of 1,3-dinitrobenzene and 1,3,5-trinitrobenzene. *Polycyclic Aromatic Compounds* **21**:187-201.
41. O'Neil WM, Drobitch RK, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, Crane LR, and Svensson CK (2000) Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. *Pharmacogenetics* **10**:171-182.
42. Ohtake PJ, Simakajornboon N, Fehniger MD, Xue YD, and Gozal D (2000) N-Methyl-D-aspartate receptor expression in the nucleus tractus solitarius and maturation of hypoxic ventilatory response in the rat. *Am.J.Respir.Crit Care Med.* **162**:1140-1147.
43. Petrikovics I, Cheng TC, Papahadjopoulos D, Hong K, Yin R, DeFrank JJ, Jaing J, Song ZH, McGuinn WD, Sylvester D, Pei L, Madec J, Tamulinas C, Jaszberenyi JC, Barcza T, and Way JL (2000) Long circulating liposomes encapsulating organophosphorus acid anhydrolase in diisopropylfluorophosphate antagonism. *Toxicol.Sci.* **57**:16-21.
44. Purewal M, Velasco M, Fretland AJ, Hein DW, and Wargovich MJ (2000) 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine induces a higher number of aberrant crypt foci in Fischer 344 (rapid) than in Wistar Kyoto (slow) acetylator inbred rats. *Cancer Epidemiol.Biomarkers Prev.* **9**:529-532.
45. Purewal M, Fretland AJ, Schut HA, Hein DW, and Wargovich MJ (2000) Association between acetylator genotype and 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) DNA adduct formation in colon and prostate of inbred Fischer 344 and Wistar Kyoto rats. *Cancer Lett.* **149**:53-60.
46. Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, and Svensson CK (2000) A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. *J.Invest Dermatol.* **114**:1164-1173.
47. Ren J, Wold LE, and Epstein PN (2000) Diabetes enhances acetaldehyde-induced depression of cardiac myocyte contraction. *Biochem.Biophys.Res.Commun.* **269**:697-703.
48. Reyes GF, Corbett D, Benz FW, and Doyle RJ (2000) Acrylonitrile induces autolysis *Bacillus subtilis*. *FEMS Microbiol.Lett.* **182**:255-258.
49. Schurr A and Payne RS (2000) NADH shuttle and insulin secretion (technical comment). *Science* **287**:931.
50. Simakajornboon N, Gozal E, Gozal YM, and Gozal D (2000) Hypoxia induces activation of a N-methyl-D-aspartate glutamate receptor- protein kinase C pathway in the dorsocaudal brainstem of the conscious rat. *Neurosci.Lett.* **278**:17-20.

51. Song LL, Myers SR, Lantvit D, Lubet RA, Steele VE, Kelloff GJ, Moon RC, and Pezzuto JM (2000) Chemoprevention of DMBA-induced mammary carcinogenesis: Relationship between induction of phase II enzymes, effects on DMBA-induced hemoglobin adducts and decreases in mammary tumor multiplicity. *Polycyclic Aromatic Compounds* **18**:193-210.
52. Song ZH and Slowey CA (2000) Involvement of cannabinoid receptors in the intraocular pressure- lowering effects of WIN55212-2. *J.Pharmacol.Exp.Ther.* **292**:136-139.
53. Song ZH and Zhong M (2000) CB1 cannabinoid receptor-mediated cell migration. *J.Pharmacol.Exp.Ther.* **294**:204-209.
54. Srivastava S, Dixit BL, Cai J, Sharma S, Hurst HE, Bhatnagar A, and Srivastava SK (2000) Metabolism of lipid peroxidation product, 4-hydroxynonenal (HNE) in rat erythrocytes: role of aldose reductase. *Free Radic.Biol.Med.* **29**:642-651.
55. States JC, McGregor WG, and Ljungman M (2000) Second annual midwest DNA repair symposium, University of Louisville, Louisville, KY, 20-21 May 2000. *Mutation Res.* **461**:163-167.
56. Steffensen IL, Fretland AJ, Paulsen JE, Feng Y, Eide TJ, Devanaboyina US, Hein DW, and Alexander J (2000) DNA adduct levels and intestinal lesions in congenic rapid and slow acetylator Syrian hamsters administered food mutagens 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine(PhIP) or 2-amino-3-methylimidazo[4,5-f]quinoline(IQ). *Pharmacol.Toxicol.* **86**:257-263.
57. Suzuki M, Tsueda K, Lansing PS, Tolan MM, Fuhrman TM, Sheppard RA, Hurst HE, and Lippmann SB (2000) Midazolam attenuates ketamine-induced abnormal perception and thought process but not mood changes. *Can.J.Anaesth.* **47**:866-874.
58. Thakkar RR, Wang OL, Zerouga M, Stillwell W, Haq A, Kissling R, Pierce WM, Smith NB, Miller FN, and Ehringer WD (2000) Docosahexaenoic acid reverses cyclosporin A-induced changes in membrane structure and function. *Biochim.Biophys.Acta* **1474**:183-195.
59. Waalkes MP, Fox DA, States JC, Patierno SR, and McCabe MJ (2000) Metals and disorders of cell accumulation: modulation of apoptosis and cell proliferation. *Toxicol.Sci.* **56**:255-261.
60. Waddell WJ and Levy PS (2000) Re: "Interaction between tobacco and alcohol consumption and the risk of cancers of the upper aero-digestive tract in Brazil". *Am.J.Epidemiol.* **152**:193-194.
61. Whitney GM, Ohtake PJ, Simakajornboon N, Xue YD, and Gozal D (2000) AMPA glutamate receptors and respiratory control in the developing rat: anatomic and pharmacological aspects. *Am.J.Physiol Regul.Integr.Comp Physiol* **278**:R520-R528.
62. Zhou Z and Kang YJ (2000) Immunocytochemical localization of metallothionein and its relation to doxorubicin toxicity in transgenic mouse heart. *Am.J.Pathol.* **156**:1653-1662.

63. Zhou Z and Kang YJ (2000) Cellular and subcellular localization of catalase in the heart of transgenic mice. *J.Histochem.Cytochem.* **48**:585-594.

### **Additional Publications of Faculty with Joint Appointments**

1. Blankenship KA, Dawson CB, Aronoff GR, and Dean WL (2000) Tyrosine phosphorylation of human platelet plasma membrane Ca(2+)- ATPase in hypertension. *Hypertension* **35**:103-107.
2. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, and Tracey KJ (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* **405**:458-462.
3. Eaton JW and Dean R (2000) Diabetes and atherosclerosis, in *Atherosclerosis* (Dean R and Kelly D eds) pp 24-45, Oxford University Press, London.
4. Ehringer WD, Wang OL, Haq A, and Miller FN (2000) Bradykinin and alpha-thrombin increase human umbilical vein endothelial macromolecular permeability by different mechanisms. *Inflammation* **24**:175-193.
5. Galbreath KC, Toman DL, Zygarlicke CJ, Huggins FE, Huffman GP, and Wong JL (2000) Nickel speciation of residual oil fly ash and ambient particulate matter using X-ray absorption spectroscopy. *J.Air Waste Manag.Assoc.* **50**:1876-1886.
6. Garner B, Roberg K, Qian M, Eaton JW, and Truscott RJ (2000) Distribution of ferritin and redox-active transition metals in normal and cataractous human lenses. *Exp.Eye Res.* **71**:599-607.
7. Goth L and Eaton JW (2000) Hereditary catalase deficiencies and increased risk of diabetes. *Lancet* **356**:1820-1821.
8. Greene RM and Pisano MM (2000) Pathways to transcription. *Teratology* **62**:10-13.
9. Kusek JC, Greene RM, Nugent P, and Pisano MM (2000) Expression of the E2F family of transcription factors during murine development. *Int.J.Dev.Biol.* **44**:267-277.
10. Liu A and Wong JL (2000) Chemical speciation of nickel in fly ash by phase separation and carbon paste electrode voltammetry. *J.Hazard.Mater.* **74**:25-35.
11. Miller DM and Castillos FA (2000) New approaches to screening for cervical cancer in high-risk populations. *J.Lab Clin.Med.* **135**:12-13.
12. Montgomery VL, Sullivan JE, and Buchino JJ (2000) Prognostic value of pre- and postoperative cardiac troponin I measurement in children having cardiac surgery. *Pediatr.Dev.Pathol.* **3**:53-60.



13. Pisano MM and Greene RM (2000) Palate development. In vitro procedures. *Methods Mol.Biol.* **137**:267-274.
14. Qian M and Eaton JW (2000) Glycochelates and the etiology of diabetic peripheral neuropathy. *Free Radic.Biol.Med.* **28**:652-656.
15. Qian M and Eaton JW (2000) Transition metal chelators: Possible new therapies for diabetic complications, in *Iron Chelators: New Development Strategies* (Badman DG, Bergeron RJ, and Brittenham GM eds) pp 399-414, Saratoga Publishing Group, Ponte Verda, Florida.
16. Schuschke DA, Falcone JC, Saari JT, Fleming JT, Percival SS, Young SA, Pass JM, and Miller FN (2000) Endothelial cell calcium mobilization to acetylcholine is attenuated in copper-deficient rats. *Endothelium* **7**:83-92.
17. Subramanian A and Miller DM (2000) Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. *J.Biol.Chem.* **275**:5958-5965.
18. Sullivan JE and Berman BW (2000) The pediatric forum: hypermagnesemia with lethargy and hypotonia due to administration of magnesium hydroxide to a 4-week-Old infant. *Arch.Pediatr.Adolesc.Med.* **154**:1272-1274.
19. Thakkar RR, Wang OL, Zerouga M, Stillwell W, Haq A, Kissling R, Pierce WM, Smith NB, Miller FN, and Ehringer WD (2000) Docosahexaenoic acid reverses cyclosporin A-induced changes in membrane structure and function. *Biochim.Biophys.Acta* **1474**:183-195.
20. Vigneswaran N, Zhao W, Dassanayake A, Muller S, Miller DM, and Zacharias W (2000) Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer. *Hum.Pathol.* **31**:931-937.
21. Wang WZ, Anderson GL, Guo SZ, Tsai TM, and Miller FN (2000) Initiation of microvascular protection by nitric oxide in late preconditioning. *J.Reconstr.Microsurg.* **16**:621-628.
22. Wang WZ, Guo SZ, Tsai TM, Anderson GL, and Miller FN (2000) Platelet-activating factor contributes to postischemic vasospasm. *J.Surg.Res.* **89**:139-146.
23. Zhao M, Eaton JW, and Brunk UT (2000) Protection against oxidant-mediated lysosomal rupture: a new anti- apoptotic activity of bcl-2? *FEBS Lett.* **485**:104-108.

## **VI. Abstracts (salaried faculty and staff)**

1. Benz, FW, J Li, D Corbett, TS Chen and DE Nerland. Neither Direct Chemical Nor Cyanide Antagonism Can Fully Explain The Antidotal Effect Of N-Acetyl-L-Cysteine On Acute Acrylonitrile Intoxication. *Toxicological Sciences* 54: No1-Supplement, 209 (2000).

2. Fu, X., T.S. Chen, D.W. Hein, and W. M. Williams. *p*-Aminophenol-induced hepatotoxicity in hamsters. *The FASEB J.* 14: A1559, 2000.
3. Chen H, Carlson EC, Moritz J, Epstein PN. Overexpression of antioxidants: catalase, superoxide dismutase and metallothionein protects transgenic mouse from streptozocin induced diabetes. *Annual Meeting of the American Diabetes Association 2000.*
4. Epstein PN, Carlson EC, Liang Q. Metallothionein Protects the Heart in a New Model of Diabetic Cardiomyopathy. *Annual Meeting of the American Diabetes Association 2000.*
5. Liang Q, Epstein PN. Yeast Hexokinase Increases Cardiac Glycolysis and Glycogen Synthesis. *Annual Meeting of the American Diabetes Association 2000.*
6. Gozal D, Gozal E. Developmental aspects of signal transduction pathways underlying hypoxic ventilatory responses. Presented at the 6<sup>th</sup> *World Congress on Sleep Apnea*, March 12-15, 2000, Sydney, Australia.
7. Gozal D, Nakamura CT, Keens TG. Passively induced overnight hypocapnia but not eucapnia improves daytime gas-exchange homeostasis in children requiring nighttime mechanical ventilation: CO<sub>2</sub> stores or respiratory drive plasticity? Presented at the *2000 Experimental Biology Meeting*, April 15 -18, 2000, San Diego, CA. Abstracted in *FASEB J.* 14:A91.4, pp. A77, 2000.
8. Jones KL, Krous HF, Nadeau J, Zielke HR, Gozal D. Vascular endothelial growth factor (VEGF) levels as an hypoxic marker in the cerebrospinal fluid (CSF) of SIDS. Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A543. 2000.
9. Simakajornboon N, Anonetapipat JW, Szerlip NJ, Gozal D. Phosphorylation of protein kinase B (Akt) and BAD kinase in the dorsocaudal brainstem (DB) during hypoxia exhibits PDGF- $\beta$  receptor (PDGFR) dependency. Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A543, 2000.
10. Simakajornboon N, Farless LB, Gozal D. Down-regulation of NMDA receptor expression in rat dorsocaudal brainstem (DB) during chronic hypoxia coincides with selective isoform changes in PKC. Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A543, 2000.
11. Vlasic V, N. Simakajornboon, Gozal D. Modulation of hypoxic ventilatory depression by PDGF- $\beta$  receptor is developmentally regulated. Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 61:A.483, 2000.

12. Gozal D, Simakajornboon N. Ventilatory effect of passive motion of lower extremities during NREM sleep in CCHS. Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A854, 2000.
13. Lipton AJ, Gaston B, Czapla MA, Gozal D. Deoxyhemoglobin (DOH) and  $\beta$ -glutamyl transpeptidase (GGT) mediate central components of hypoxia-induced short-term potentiation (STP) in the conscious rat. Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A483, 2000.
14. Vlasic V, N. Simakajornboon, Gozal D. Platelet-activating factor receptor (PAFR) inhibition reveals developmental differences in modulation of hypoxic ventilatory response (HVR). Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A485, 2000.
15. Simakajornboon N, Gozal D, Hasan SU. Prenatal cigarette smoke (CS) exposure induces selective changes in expression of protein kinase C isoforms within the dorsocaudal brainstem of the neonatal rat. Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A544, 2000.
16. Hasan SU, Simakajornboon N, Gozal D. Smoking during gestation selectively alters expression of neuronal nitric oxide synthase within the dorsocaudal brainstem of the rat. Presented at the *Pediatric Academic Societies Annual Meeting*, May 12-16, 2000, Boston, MA. Abstracted in *Pediatr. Res.* 47:70A, Abstract # 410, 2000.
17. Hasan SU, Simakajornboon N, MacKinnon Y, Gozal D. Antenatal cigarette smoke exposure induces selective changes in expression of protein kinase C isoforms within the dorsocaudal brainstem of the neonatal rat. Presented at the *Pediatric Academic Societies Annual Meeting*, May 12-16, 2000, Boston, MA. Abstracted in *Pediatr. Res.* 47:360A, Abstract # 2128, 2000.
18. Gozal D, Pope DW. Long-term impact of snoring during early childhood on academic performance in middle school. Presented at the *14<sup>th</sup> Annual APSS Meeting*, June 17-22, 2000, Las Vegas, Nevada. Abstracted in *Sleep* (Suppl. 2) 23:A29, 2000.
19. Simakajornboon N, Beckerman RC, Mack CS, Sharon D, Gozal D. Effect of supplemental oxygen on sleep architecture and cardiorespiratory events in premature infants. Presented at the *14<sup>th</sup> Annual APSS Meeting*, June 17-22, 2000, Las Vegas, Nevada. Abstracted in *Sleep* (Suppl. 2) 23:A96, 2000.
20. Yu PL, Woo MA, Woo MS, Keens TG, Saeed MM, Gozal D, Alger J, Harper RM. Visualization of neural activity by functional magnetic resonance imaging to hyperoxia in congenital Central Hypoventilation Syndrome. Presented at the *14<sup>th</sup> Annual APSS Meeting*, June 17-22, 2000, Las Vegas, Nevada. Abstracted in *Sleep* (Suppl. 2) 23:A346, 2000.

21. Macey KE, Kuo L, Kim A, Yu PL, Woo MA, Saeed MM, Gozal D, Harper RM. Breathing patterns following hypercapnia in Congenital Central Hypoventilation Syndrome. Presented at the *14<sup>th</sup> Annual APSS Meeting*, June 17-22, 2000, Las Vegas, Nevada. Abstracted in *Sleep* (Suppl. 2) 23:A16, 2000.
22. Alger JR, Woo MA, Woo MS, Saeed MM, Yu P, Gozal D, Keens TG, Harper RM. An "oxygen paradox": The influence of inspired gases in "BOLD" functional magnetic resonance neuroimaging. Presented at the *2000 Annual Meeting of the International Society of Magnetic Resonance in Medicine*, Denver, CO.
23. Lipton AJ, Lieberman MW, Gaston B, Gozal D. Absence of short-term potentiation of ventilation (STP) after hypoxia in  $\beta$ -glutamyl transpeptidase (GGT)-deficient mice. Presented at the *30th Annual Meeting of the Society for the Neurosciences*, 4-9 November, 2000, New Orleans, LA, Vol. 26. Abstract # 210.6, page 556.
24. Guo SZ, Cheng Z, Gozal D. Dose-dependent attenuation of hypoxic ventilatory response in waking rats following domoic acid lesions in nucleus of solitary tract. Presented at the *30th Annual Meeting of the Society for the Neurosciences*, 4-9 November, 2000, New Orleans, LA, Vol. 26. Abstract # 210.2, page 556.
25. Gozal E, Klein JB, Pierce WM, Cai J, Scherzer JA, Sachleben LR, Gozal D. Proteomic analysis of CA1 and CA3 regions of hippocampus following 6 hours of intermittent hypoxia. Presented at the *30th Annual Meeting of the Society for the Neurosciences*, 4-9 November, 2000, New Orleans, LA, Vol. 26. Abstract # 655.12, page 1755.
26. Yu PL, Kim AH, Kuo L, Saeed MM, Alger JR, Woo MA, Gozal D, Keens TG, Harper RM. Functional magnetic resonance imaging (fMRI) during cold pressor challenges in congenital central hypoventilation syndrome (CCHS). Presented at the *30th Annual Meeting of the Society for the Neurosciences*, 4-9 November, 2000, New Orleans, LA, Vol. 26. Abstract #210.12 , page 557.
27. Kim AH, Woo MA, Macey PM, Yu PL, Frysinger RC, Keens TG, Gozal D, Harper RK, Harper RM. Heart rate variability during cold pressor challenges in congenital central hypoventilation syndrome. Presented at the *30th Annual Meeting of the Society for the Neurosciences*, 4-9 November, 2000, New Orleans, LA, Vol. 26. Abstract #210.11, page 557.
28. Harper RM, Yu PL, Saeed MM, Alger JR, Woo MA, Gozal D, Keens TG. Time trends of cerebellar fastigial nucleus responses to hypercapnia in congenital central hypoventilation syndrome. Presented at the *30th Annual Meeting of the Society for the Neurosciences*, 4-9 November, 2000, New Orleans, LA, Vol. 26. Abstract #210.10, page 557.

29. Czapla MA, Gozal D, Zadina JE. Endomorphin-1 induces analgesia with less respiratory depression than other mu-opioid agonists. Presented at the *30th Annual Meeting of the Society for the Neurosciences*, November 4-9, 2000, New Orleans, LA, Vol. 26. Abstract #238.7, page 634.
30. Ortiz L, Lasky J, Gozal E, Lungarella G, Martorana P, Cavarra E, Pardo M, Friedman M, Selman M. Altered MMP-13/TIMP-1 RNA expression and decreased AP-1, but not NF- $\kappa$ B, activation characterize TNF receptor knockout mice resistance to silica. Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Ontario, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A 481, 2000.
31. Gozal E, Ortiz L, Zou X, Reyes M, Burow M, Lasky J, Friedman M. Role of TNF- $\alpha$ " and NF- $\kappa$ B in silica induced apoptosis of Raw 264-7 and IC-21 murine macrophage cell lines. Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Ontario, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A 666, 2000.
32. Kafoury RM, Gozal E, Squadrito GL, Zou X, Pryor WA, Friedman M. Lipid ozonation products (LOP) activate nuclear factors NF-IL6 and NF- $\kappa$ B and release interleukin-8 (IL8) in human bronchial epithelial cells (BEAS-2B). Presented at the *2000 ALA/ATS International Conference*, May 5-10, 2000, Toronto, Ontario, Canada. Abstracted in *Am. J. Resp. Crit. Care Med.* 161:A 615, 2000.
33. Gozal E, Klein JB, Pierce WM, Scherzer JA, Cai J, Sachleben LR. Proteomic analysis of CA1 and CA3 regions of hippocampus following 6 hours of intermittent hypoxia. Presented at *30th Annual Meeting of the Society for the Neuroscience*, 4-9 November, 2000, New Orleans, LA.
34. Fretland, A.J., Devanboyina, U.-S., Feng, Y., Leff, M.A., Xiao, G.H., Webb, S.J., and Hein, D.W. DNA adducts but not tumors in rapid and slow acetylator male congenic hamsters administered 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) or N-hydroxy-PhIP. *Proceedings of the American Association for Cancer Research* 41:422, 2000.
35. Nangju, N.A., Doll, M.A., Xiao, G.H., Devanaboyina, U.-S., Fretland, A.J., and Hein, D.W. Acetylator genotype (*NAT2*)-dependent metabolic activation of 2-hydroxy-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) by mammary epithelial cells derived from rapid and slow acetylator hamsters congenic at the *NAT2* locus. *Proceedings of the American Association for Cancer Research* 41:835, 2000.
36. Deitz, A.C., Garcia-Closas, M., Rothman, N., Hayes, R.B., Chow, W., Hein, D.W., and Rebbeck, T.R. Impact of misclassification in genotype-disease association studies: Example of N-acetyltransferase 2 (*NAT2*), smoking and bladder cancer. *Proceedings of the American Association for Cancer Research* 41:559, 2000.

37. Lan, Q., Chow, W.-H., Lissowska, J., Zatonski, W., Hein, D., and Rothman, N. GSTM1, GSTT1, GSTP1 genotypes and stomach cancer in a population-based case-control study in Warsaw, Poland (abstract presented at meeting was revised and updated from published). *Proceedings of the American Association for Cancer Research* 41:582, 2000.
38. Webb, S.J., Xiao, G.H., and Hein, D.W. Real-time quantitative RT-PCR analysis of NAT1 and NAT2 mRNA expression in the rapid and slow acetylator congenic Syrian hamster. *The FASEB Journal* 14:A1446, 2000.
39. Hein, D.W., Leff, M.A., Ishibe, N., Sinha, R., Berlot, J., Frame, J., Frazier, H.A., Doll, M.A., Weinrich, M.C., and Caporaso, N.E. Slow N-acetyltransferase and null glutathione-S-transferase genotypes and prostate cancer risk. *Proceedings of the joint meeting of the American Society for Biochemistry and Molecular Biology/American Society for Pharmacology and Experimental Therapeutics*, #LB64, Boston, MA, June 2000.
40. Nangju, N.A., Doll, M.A., Xiao, G.H., and Hein, D.W. Acetylator genotype (NAT2)-dependent metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by colon and mammary epithelial cells derived from rapid and slow acetylator hamsters congenic at the NAT2 locus. *Proceedings of the Ohio Valley Society of Toxicology*, Cincinnati, Ohio, October 2000.
41. Hein, D.W., Leff, M.A., Ishibe, N., Sinha, R., Berlot, J., Frame, J., Frazier, H.A., Doll, M.A., Weinrich, M.C. and Caporaso, N.E. Slow N-acetyltransferase and null glutathione-S-transferase genotypes and prostate cancer risk. *Proceedings of the Ohio Valley Society of Toxicology*, Cincinnati, Ohio, October 2000.
42. Xiao, G.H., Doll, M.A., Webb, S.J., Fretland, A.J. and Hein, D.W. Functional analysis of rapid and slow acetylator congenic hamster N-acetyltransferase 1 (NAT1) and 2 (NAT2). *Proceedings of the Ohio Valley Society of Toxicology*, Cincinnati, Ohio, October 2000.
43. Fretland, A.J., Doll, M.A., Leff, M.A., and Hein, D.W. Effect of nucleotide substitutions in N-acetyltransferase-1 (NAT1) on metabolic deactivation (N-acetylation) and activation (O-acetylation) of arylamine carcinogens: Implications for cancer predisposition. *Cancer Detection and Prevention* 24/Supplement 1:S-166, 2000.
44. Hein, D.W., Leff, M.A., Ishibe, N., Sinha, R., Berlot, J., Frame, J., Frazier, H.A., Doll, M.A., Weinrich, M.C. and Caporaso, N.E. Slow N-acetyltransferase and null glutathione-S-transferase genotypes and prostate cancer risk. *Proceedings of Research!Louisville 2000*, Louisville, Kentucky, October 2000.
45. Xiao, G.H., Doll, M.A., Webb, S.J., Fretland, A.J. and Hein, D.W. Functional analysis of rapid and slow acetylator congenic hamster N-acetyltransferase 1 (NAT1) and 2 (NAT2). *Proceedings of Research!Louisville 2000*, Louisville, Kentucky, October 2000.

46. Cai, J. and Hurst, H.E. Use of mass spectrometry to investigate the role of glycosylated hemoglobin in formation of N-(carboxymethyl)valine adduct in hemoglobin. Abstract Log Number 568 presented at the 48th ASMS Conference on Mass Spectrometry and Allied Topics, Long Beach, CA, June 11 - 15, 2000.
47. Morgan, J., Cai, J., Mokshagundam, S., Mastropaolo, W., and Hurst, H.E. Examination of the N-(carboxymethyl)valine hemoglobin adduct as a marker for complications in diabetes mellitus. Research!Louisville 2000 Student Research Day, October 30, 2000.
48. Kang, Y. J., Kehrer, J. P., Robbins, J., and Wallace, K. B. Molecular approaches to comprehensive understanding of cardiotoxicity. *Toxicol. Sci. (The Toxicologist)* 54 (1-S):1, 2000.
49. Kang, Y. J., and Waalkes, M. P. Metallothionein subcellular localization and regulation of cell cycle and apoptosis. *Toxicol. Sci. (The Toxicologist)* 54 (1-S):411, 2000.
50. Kang, Y. J., Wang, G.-W., Zhou, Z.-X., and Klein, J. B. Inhibition by metallothionein of oxidative stress-induced apoptosis. *Toxicol. Sci. (The Toxicologist)* 54 (1-S):411, 2000.
51. Lambert, J. C., Wang, G.-W., and Kang, Y. J. Suppression by zinc of doxorubicin-induced apoptosis: Inhibition of caspase-3 activation. *Toxicol. Sci. (The Toxicologist)* 54 (1-S):112, 2000.
52. Wang, G.-W., Zhou, Z.-X., and Kang, Y. J. Effect of metallothionein on doxorubicin-induced apoptosis in cardiomyocytes: Role of cytochrome c-activated caspase-3. *Toxicol. Sci. (The Toxicologist)* 54 (1-S):114, 2000.
53. Klein, J. B., Wang, G.-W., Zhou, Z.-X., Buridi, A., and Kang, Y. J. TNF- $\alpha$  stimulates cardiomyocyte apoptosis by a p38 MAPK-dependent pathway requiring reactive oxygen species. *Toxicol. Sci. (The Toxicologist)* 54 (1-S):131, 2000.
54. Zhou, Z.-X., and Kang, Y. J. Immunogold localization of metallothionein and subcellular protection against doxorubicin toxicity in transgenic mouse hearts. *Toxicol. Sci. (The Toxicologist)* 54 (1-S):347, 2000.
55. Sun, X.C., Zhou, Z.-X., and Kang, Y. J. Anti-apoptotic effect of metallothionein contributes to its inhibition of ischemia/reperfusion-induced infarction in mouse hearts. *Toxicol. Sci. (The Toxicologist)* 54 (1-S):347, 2000.
56. Zhou, Z., Zhong, X., and Kang, Y. J. Ethanol-induced apoptosis in mouse liver: Cytochrome c-activated caspase-3 pathway. *Digestive Disease Week*, 2000. Abstract #984.
57. Zhong, X., Zhou, Z., and Kang, Y. J. Metallothionein protects against alcoholic liver injury in mice through inhibition of oxidative stress. *Digestive Disease Week*, 2000. Abstract #125.

58. El-Sherif, L., Wang, G.-W., and Kang, Y. J. Suppression of cadmium-induced apoptosis in metallothionein-overexpressing transgenic mouse cardiomyocytes. *FASEB J.* 14 (8), 2000: Abstract #1193.
59. Lambert, J. C. and Kang, Y. J. Inhibition of caspase-3 activation by zinc does not suppress cell death in H9C2 cells. *Research!Louisville*, 2000.
60. Sun, X., Zhou, Z., and Kang, Y. J. Metallothionein protects the heart from doxorubicin chronic toxicity. *Research!Louisville*, 2000.
61. Zhou, Z. Sun, X., and Kang, Y. J. Protection by metallothionein from alcohol liver injury in mice through inhibition of oxidative stress. *Research!Louisville*, 2000.
62. Cai, L., Klein, J. B. and Kang, Y. J. Preventive effect of metallothionein on diabetic cardiomyopathy. *Research!Louisville*, 2000.
63. Wang, X., Li, Z., McManus, T. McGregor, W.G., Lawrence, C.W. and Maher, V.M. Expression of *hREVI* antisense RNA significantly reduces the frequency of UV-induced mutations in human fibroblasts. *Midwest DNA Repair Symposium*, University of Louisville, May 20, 2000.
64. N. Tampal, S. Myers, D. Pereg, and L. Robertson. Hemoglobin adducts of polychlorinated biphenyls as potential biomarkers of exposure. *Toxicologist* 54:1, 77, 2000.
65. Shoemaker, L., WM Pierce, Jr. Furosemide-Induced Hypercalcuria: A Model of Hypercalcuric Bartter Syndrome (HBS). Presented at the *American Academy of Pediatrics* annual meeting, May 12, 2000, Boston, MA, USA.
66. William M. Pierce Jr., K. Grant Taylor, Leonard C. Waite, Sujan Singh, Jason R. Neale, Xiaoping Tang, and Ned B. Smith. Bone-targeted Estrogens: Anabolic Bone Effects of an Ether-linked 17-O-Estradiol Derivative. *J. Bone Mineral Res.*, 2000
67. K. Grant Taylor, Jason R. Neale, Sujan Singh, Xiaoping Tang, Peter C. Kulakosky, Valentyn V. Tyulmenkov, Leonard C. Waite, Carolyn M. Klinge, and William M. Pierce, Jr. Bone selective estrogens: Estrogen receptor alpha selectivity is a predictor of *in vivo* efficacy. Presented at the annual meeting of the *American Chemical Society - Southeast / Southwest Regions*.
68. Klein, J.B., J.J. Williams, J.A. Scherzer, J. Cai, W.M. Pierce and J.M. Arthur. Development of a protein expression database and comparison of rat renal cortical and medullary protein expression using high-throughput proteomic analysis. *J. Am. Soc. Nephrol.* 11:409A, 2000.
69. Arthur, J.M., J.J. Williams, J.A. Scherzer, J. Cai, W.M. Pierce and J.B. Klein. Proteomic identification of proteins involved in magnesium reabsorption in the kidney. *J. Am. Soc. Nephrol.* 11:557A, 2000.



70. Rosecrans J.A., James J.R. and Rowell P.P. Correlations between the sensitivity of the behavioral effects of nicotine and differences in brain area nicotine binding: Fischer-344 vs. Sprague-Dawley rats. *SRNT Abstracts*, Feb. 2000.
71. Rowell P.P., Volk K.A., Li J. and Bickford M.E. Cholinergic control of GABA release in the rat thalamus. *Soc. Neurosci. Absrt.* 26:1911, 2000.
72. Donny E.C., Caggiula A.R., P.P. Rowell, P.P., Gharib M.A., Maldovan V., Booth S., Hoffman A., Mielke M.M. and McCallum S. Nicotinic receptor binding and plasma and brain nicotine levels following nicotine self-administration in male and female rats. *Soc. Neurosci. Absrt.* 26:528, 2000.
73. Rowell P.P and Volk K.A. Characterization of nicotine-stimulated  $^{86}\text{Rb}^+$  efflux from rat ventral tegmental slices. Neuronal Nicotinic Receptors, *10th Neuropharmacology Conference*, Nov. 2-4, 2000.
74. Z. H. Song and Shuang Zhao. Absence of a conserved proline in the CB2 cannabinoid receptor is crucial for receptor activation. *American Society of Pharmacology and Experimental Therapeutics 2000 meeting*.
75. Shuang Zhao, Patricia H. Reggio, and Z. H. Song. Molecular basis for the CB2 selectivity of a novel C-1 ether of classical cannabinoid. *International Cannabinoid Research Society 2000 Symposium on the Cannabinoids*.
76. Dan Zhou and Z. H. Song. CB1 cannabinoid receptor mediates neurite remodeling in mouse neuroblastoma cell N1E-115. *Research!Louisville 2000*.
77. States, JC and Kaplan, DJ. Induction of XPA by cisplatin in cisplatin resistant ovarian carcinoma cells. *Toxicological Sciences* 54(1):1004, 2000.
78. Porter, PC, Mellon, I and States, JC. Candidate polymorphism in the DNA binding domain of XPA. *Second Annual Midwest DNA Repair Symposium*, Louisville, KY (2000)
79. Jones, JK and States, JC. DNA repair gene expression in ovarian cancer cells. *Research!Louisville*, Louisville, KY, 2000.
80. Porter, PC, Mellon, I and States, JC. Single nucleotide polymorphisms in exons 4, 5 and 6 of the essential nucleotide excision repair gene XPA. *Research!Louisville*, Louisville, KY, 2000.
81. Jiang, GH, Skovvaga, M, van Houten, B and States, JC. Specific incision BPDE-DNA adducts with thermal-resistant UVRABC excision nuclease from *B. Caldotenax*. *Research!Louisville*, Louisville, KY, 2000.

82. Reid, K.H., Li, G.Y., Payne, R.S., Schurr, A., Cooper, N.G.F. Early glucose preloading normalizes KCC2 mRNA in the inferior colliculus of the post-ischemic audiogenic seizure-prone rat. *Soc. Neurosci. Abst.* 26:739, 2000.
83. Schurr, A., Payne, R.S., Miller, J.J., Schechter, Y., Rigor, B.M. Vangdate abolishes preischemic hyperglycemia-enhanced neuronal damage in vivo. *Soc. Neurosci. Abst.* 26:764, 2000.
84. Payne, R.S., Schechter, Y., Rigor, B.M., Schurr, A. Vangdate antagonizes corticosterone-enhanced ischemic neuronal damage in vitro. *Soc. Neurosci. Abst.* 26:764, 2000.

## VII. Invited Scientific Presentations and Seminars (salaried faculty)

### Dr. David Gozal

*The Brainstem: MRI/PET Evidence.* Keynote Speaker, 18<sup>th</sup> Annenberg Annual Conference on Sleep Disorders in Infants and Children, 20-22 January 2000, Rancho Mirage CA.

*Central Chemoreception: Developmental Aspects.* Invited Speaker, C.I.P.P. IV (Congres International Pneumologie Pediatrique), 21-24 February 2000, Nice, France.

*Home ventilation.* Invited Speaker, C.I.P.P. IV (Congres International Pneumologie Pediatrique), 21-24 February 2000, Nice, France.

*Developmental Aspects of Signal Transduction Pathways Underlying Hypoxic Ventilatory Responses.* Invited Speaker, 6<sup>th</sup> World Congress on Sleep Apnea, 12-15 March, 2000, Darling Harbour Convention Center, Sydney, Australia.

*Signal Transduction During Hypoxia in the Nucleus Tractus Solitarii.* Invited Speaker, 7<sup>th</sup> International Symposium on Sleep and Breathing, 16-17 March, 2000, Manly Pacific Parkroyal Hotel, Manly, Australia.

*Infantile Apnea: Cardiovascular Interactions.* Invited Speaker, 7<sup>th</sup> International Symposium on Sleep and Breathing, 16-17 March, 2000, Manly Pacific Parkroyal Hotel, Manly, Australia.

*Neurocognitive Sequelae of Obstructive Sleep Apnea in Children.* Invited Speaker, Pediatric Academic Societies Meeting, May 12-16, 2000, Boston, MA.

*Snoring in Children: Is It Really Benign?* Grand Rounds, Department of Family and Community Medicine, University of Louisville, 19 May 2000, Louisville, KY.

*Growth Factor Modulation of Hypoxic Ventilatory Response.* Research Seminar, Respiratory Research Group, University of Calgary, 23 June 2000, Calgary, Alberta, Canada.

*Growth Factor Modulation of Hypoxic Ventilatory Response: Implications for Development, Adaptation and Survival.* Research Seminar, Division of Neuroscience and Perinatal Research Group, University of Alberta, 6 June 2000, Edmonton, Alberta, Canada.

*Pediatric Sleep Medicine - An Overview.* Pediatric/Adult Sleep Medicine for the Technologist, Kentucky Sleep Society, Kramner Auditorium, Norton Healthcare Pavillion, 3 August 2000, Louisville, KY.

*Potential Roles for Growth Factor Receptors within Brainstem Neurons.* Research Seminar, Section of Pediatric Respiratory Medicine, Yale University School of Medicine, 8 September 2000, New Haven, CT.

*Pediatric Obstructive Sleep Apnea and its Consequences.* Yale University Symposium on Sleep Medicine: An Update for Primary Care Providers, Pediatricians, and Family Physicians, Foxwood Resort and Conference Center, 9 September 2000, Mashantucket, CT.

*Non-Invasive Ventilation in Children.* 2<sup>nd</sup> Pediatric Fellows Conference, American College of Chest Physicians Annual Meeting, 21 October 2000, San Francisco, CA.

*NIH Funding and the Clinician-Scientist: The Promised Land.* A Panel Discussion on Grant Writing and Review, Jewish Hospital, Bottigheimer Auditorium, November 3, 2000, Louisville, KY.

*Apnea in the NICU Graduate: Is the Alarming Trend of Events Justified?* Eighth Newborn and Pediatric Symposium, Hyatt Regency, November 10, 2000, Louisville, KY.

*Obstructive Sleep Apnea in Children* Kentucky Sleep Society 2<sup>nd</sup> Annual Conference, Keeneland Health Education Center at St. Joseph Hospital, November 18, 2000, Lexington, KY.

*Multidisciplinary Approaches to Thematic Research: Interface and Implementation.* University of Lyon 1, Departments of Biology and Exercise Sciences, 7 December, 2000, Lyon, France.

*Intermittent and Chronic Hypoxia: Differences and Similarities.* University of Lyon 1, Departments of Biology and Exercise Sciences, 7 December, 2000, Lyon, France.

*The Snoring Child: A Good Reason to Learn your A, B, Zzzz's.* Grand Rounds, Dricoll Children's Hospital, 15 December 2000, Corpus Christi, TX.

**Dr. Evelyne Gozal**

*Kinase systems and the Hypoxic Response.* Research Conference. Kidney Disease Program. University of Louisville, March 24, 2000.

*Neuronal Susceptibility in Intermittent Hypoxia: Yes, No, Maybe?* Departmental Seminar. Department of Pharmacology and Toxicology, University of Louisville. October 12, 2000.

**Dr. David W. Hein**

*Post-Tenure Review.* Association for Medical School Pharmacology, Sea Island, Georgia, February 2000.

*Molecular Genetic Investigations of Prostate Cancer Susceptibility.* Center for Environmental and Occupational Health Sciences, University of Louisville, Louisville, Kentucky, April 2000.

*The Role of Arylamine N-Acetyltransferases in Genetic Predisposition to Breast Cancer.* Symposium on Pharmacogenetics of the Arylamine N-Acetyltransferases: A Symposium in Honor of Wendell W. Weber, Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics and the American Society of Biochemistry and Molecular Biology, Boston, Massachusetts, June 2000.

*Genetic Predisposition to Breast Cancer-Relationship of N-acetyltransferase Genotypes, Diet, and Smoking.* Center for Genetics and Molecular Medicine, University of Louisville, Louisville, Kentucky, September 2000.

*Molecular Genetics of the Acetyltransferases: A Role in Genetic Predisposition to Breast Cancer.* University of Kentucky College of Pharmacy, Lexington, Kentucky, September 2000.

*Role of Acetylation Polymorphisms in Breast Cancer Risk.* University of Cincinnati College of Pharmacy, Cincinnati, Ohio, October 2000.

*Effect of Nucleotide Substitutions in N-Acetyltransferase-1 (NAT1) on Metabolic Deactivation (N-Acetylation) and Activation (O-Acetylation) of Arylamine Carcinogens: Implications for Cancer Predisposition.* Symposium entitled Genetic Predisposition. Presented at Fifth International Symposium on Predictive Oncology and Therapy, Impact of Biotechnology on Cancer, Geneva, Switzerland, October 2000.

**Dr. Y. J. Kang**

Dec 6, 2000, University of Kentucky, Graduate Center for Nutritional Sciences, Lexington, Kentucky, "Suppression of Copper Deficiency-induced Cardiomyopathy in Metallothionein-overexpressing Transgenic Mice."

July 11, 2000, The Institute of Hygiene and Preventive Medicine of Shenyang, China, "Alcoholic liver disease."

June 30, 2000, The 27<sup>th</sup> Annual Meeting of Japanese Society of Toxicology, Yokohama, Japan, “Novel insights into the antioxidant action of metallothionein in the heart.”

June 29, 2000, The 11<sup>th</sup> Annual Meeting of the Japan Society for Biomedical Research on Trace Elements, Nagoya, Japan, “The role of oxidative stress in copper deficiency-induced cardiomyopathy.”

June 27, 2000, National Institute for Environmental Studies, Tsukuba, Japan, “The antioxidant function of metallothionein.”

Apr 26, 2000, The 8<sup>th</sup> Annual Pre-Derby Gastroenterology Conference, Louisville, Kentucky. “Alcoholic liver injury: Experimental approaches and clinical implications.”

Apr 14, 2000, Invited Lecture, Department of Toxicology, West China University of Medical Sciences, Chengdu, China. “Alcoholic liver diseases and preventive medicine.”

Apr 14, 2000, West China University of Medical Sciences, Chengdu, China. “Antioxidant function of metallothionein.”

Mar 23, 2000, “*Metallothionein Subcellular Localization and Regulation of Cell Cycle and Apoptosis*” (Chaired by Y. J. Kang and M. P. Waalkes) at the 39<sup>th</sup> Annual Meeting of Society of Toxicology, Philadelphia, PA. “Inhibition by metallothionein of oxidative stress-induced apoptosis.”

Mar 19, 2000, Continuing Education Course “*Molecular Approaches to a Comprehensive Understanding of cardiotoxicity*” (Chaired by Y. J. Kang) at the 39<sup>th</sup> Annual Meeting of Society of Toxicology, Philadelphia, PA. “Molecular Approaches to Cardiac Toxicology Research.”

Feb 17, 2000, Preventive Medical College of Norman Bethune University of Medical Sciences, Changchun, China. “Molecular medicine research and clinical applications.”

Feb 16, 2000, Department of Infectious Diseases, the First Facilitated Hospital, Norman Bethune University of Medical Sciences, Changchun, China. “Alcoholic liver diseases and alternative medicine.”

Feb 15, 2000, Department of Hematopointic Disorders, the First Facilitated Hospital, Norman Bethune University of Medical Sciences, Changchun, China. “The antioxidant function of metallothionein: Experimental approaches and clinical implications.”

**Dr. W. Glenn McGregor**

“*Mechanisms of mutation avoidance and induction in human cells,*” Graduate Center for Toxicology, University of Kentucky, February 21, 2000.

**Dr. Steven R. Myers**

*“Molecular biomarkers in toxicology and epidemiology,”* Center for Birth Defects, University of Louisville, December 19, 2000

**Dr. William M. Pierce, Jr.**

“Bone Targeting - Drug Design and Development”. Presented to Department of Biochemistry and Molecular Biology, January 21, 2000.

"Bone Targeted Estrogens". Presented to Institute for Molecular Diversity and Drug Design, University of Louisville, March 13, 2000.

“What can biomolecular mass spectrometry do for me?” Presented to the Department of Ophthalmology and Visual Sciences, University of Louisville, October 4, 2000.

**Dr. Peter P. Rowell**

“Functional activity of nicotinic receptors in the brain.” Va. Commonwealth University Medical Center - Richmond, VA, February 17, 2000.

**Dr. Zhao-Hui Song**

Molecular pharmacology of cannabinoids, Department of Ophthalmology and Visual Sciences, University of Louisville, February, 2000.

**Dr. J. Christopher States**

“Genetics of XPA”, Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, KY, May 9, 2000.

## VIII. Research Grants and Contracts (salaried faculty)

### Research Grant and Contract Proposals Submitted

	<u>Agency</u>	<u>Budget Requested</u>
<b>Dr. Laurence Carr</b>		
From myths to evidence-based geriatrics: A comprehensive curriculum for medical students, residents, and practicing physicians (project participant) 07/01/01 –06/30/04	John A. Hartford Foundation	\$300,193
<b>Dr. Theresa Chen</b>		
Nutritional modulation of glutathione status and longevity (PI) 06/01/01 - 05/31/02	NIA Pilot Research Grant Program, NIH	\$50,000
<b>Dr. David Gozal</b>		
Episodic hypoxia, REM sleep deprivation, and hippocampal function (PI) 06/00 – 06/04	NHLBI	\$900,000
PDGF in development of hypoxic ventilatory response (PI) 06/00 – 06/04	NICHHD	\$969,529
<b>Dr. Evelyne Gozal</b>		
PDGF in development of hypoxic ventilatory response (Co-I); D. Gozal (PI) 06/00 – 06/04	NICHHD	\$969,529
<b>Dr. David W. Hein</b>		
Pharmacogenetics of drug and carcinogen metabolism (continuation) (PI) 07/01/00 – 06/30/01	NCI	\$381,010
Genetic polymorphisms and bladder cell mutagenesis (collaborator); Kent Mitchell (PI) 12/01/00 – 11/30/05	NIH	\$1,354, 394

	<u>Agency</u>	<u>Budget Requested</u>
<b>Dr. David W. Hein (cont.)</b>		
Shared instrumentation grant (Co-I); Donald Miller (PI)	NSF	\$2;000,000
Shared instrumentation grant (Co-I); James Christensen (PI)	NIH	\$146,063
Pharmacogenetics of drug and carcinogen metabolism (supplement) (PI) 07/01/00 – 06/30/02	NCI	\$20,442
Biomarkers of maternal and fetal tobacco exposure (Co-I); Steven R. Myers (PI) 04/01/01 – 03/31/04	Philip Morris External Research Program	\$2,537,659
Genetic susceptibility to vinyl chloride-induced liver cancer (Co-I); Roland Valdes (PI) 04/01/01 – 03/31/06	NIH	\$1,613,840
Molecular basis of cardiac dysfunction in organ donors (Co-I); Thomas Yeh (PI) 04/01/01 – 03/31/06	NIH	\$1,784,600
Cancer education grant program (Co-I); Norbert Burzynski (PI) 05/01/01 – 04/30/06	NIH	\$356,665
Genetic polymorphisms and bladder cell mutagenesis (Collaborator); Kent Mitchell (PI) 07/01/01 – 06/30/06	NIH	\$1,353, 861
The effect of N-acetyltransferase phenotype on nuclear and mitochondrial DNA damage in heterocyclic amine cardiotoxicity (Collaborator); Stephanie J. Webb (PI) 07/01/01 – 06/30/03	AHA Ohio Valley Affiliate	\$88,000
<b>Dr. Harrell E. Hurst</b>		
N-(carboxymethyl)valine Hemoglobin Adduct: Marker for Advanced Glycosylation End Product Formation in Diabetes (PI) 04/28/00	Intramural Research Incentive Grant, UofL	\$15,000



	<u>Agency</u>	<u>Budget Requested</u>
<b>Dr. Harrell E. Hurst (cont.)</b>		
Metabolic activation of chemical carcinogens (Co-I); Steven R. Myers (PI) 04/01/01 - 03/31/04	NIH	\$525,000
$\beta$ -glucan dendrimers that target the lectin domain of CR3 (Co-I); Gordon D. Ross (PI) 04/01/01 - 03/31/05	NIH	\$1,864,152
West Louisville partnership for environmental justice (Co-I); Steven R. Myers (PI) 04/01/01 - 03/31/03	NIH	\$400,000
Design of oligosaccharide dendrimers for tumor therapy (Co-I); Gordon D. Ross (PI) 05/01/01 - 04/30/06	NIH	\$2,011,164
Biomarkers of maternal and fetal tobacco smoke exposure (Co-I); Steven R. Myers (PI) 04/01/01 - 03/31/04	Philip Morris External Research Program	\$2,537,671
Determination of suitability and sensitivity of hemoglobin adducts for quantification of butadiene air pollutant exposure (PI) 11/01/00	Kentucky EPA EPSCoR Committee	\$298,367
<b>Dr. Y. James Kang</b>		
Oxidative stress and heart failure by copper deficiency (PI) 04/01/01 - 03/31/06	NHLBI	\$1,645,000
Prevention by metallothionein of adriamycin chronic cardiotoxicity (PI) 07/01/01 - 06/30/06	NCI	\$1,800,000
Cardiomyopathy induced by marginal copper deficiency (PI) 07/91/91 - 06/30/04	USDA	\$300,000
<b>Dr. Glenn McGregor</b>		
DNA replication proteins as potential therapeutic targets (PI) 03/01/01 - 02/28/02	Intramural	\$15,000

	<u>Agency</u>	<u>Budget Requested</u>
<b>Dr. Steven R. Myers</b>		
Metabolic activation of chemical carcinogens (PI) 04/01/01 – 03/31/04	NIH	\$525,000
Biomarkers of maternal and fetal tobacco smoke exposure (PI) 04/01/00 - 03/31/03	Philip Morris External Research Program	\$2,537,671
West Louisville partnership for environmental justice (PI) 04/01/01 - 03/31/03	NIH	\$400,000
Epidemiological study of the Paducah, Kentucky gaseous diffusion plant workers (PI) 06/01/01 – 05/31/02 (Preproposal)	NIOSH	\$1,750,000
<b>Dr. William M. Pierce, Jr.</b>		
Molecular mechanisms of bone targeted estrogens (PI) 07/01/01 – 06/30/06	NIH	\$1,800,000
Bone proteomic analysis (PI) 2001 - 2002 <i>(Pre-proposal approved - Full proposal invited for Jan 31, 2001 deadline)</i>	National Osteoporosis Foundation	\$57,000
Renal sodium phosphate transporter (Co-I); Eleanor Lederer (PI) 2000 - 2005	NIH	\$1,281,260
Cardioprotective effects of ethanol (Co-I); Aruni Bhatnagar (PI) 2001-2004	NIH	\$432,000
Analysis of PTH and dopamine receptor signaling in proximal tubules (Co-I); Eleanor Lederer (PI) 2001 - 2005	Veterans Administration	\$665,500
Resveratrol responsiveness in mammary and endothelial cells (Co-I); Carolyn M. Klinge (PI) 2001-2002	AICR	\$165,000
Tyrosine phosphorylation of platelet plasma membrane Ca <sup>2+</sup> -ATPase: Role in hypertension (Collaborator); William Dean (PI) 2001-2003	AHA	\$171,324

	<u>Agency</u>	<u>Budget Requested</u>
<b>Dr. William M. Pierce, Jr.</b>		
Tempo and mode in pheromone evolution (Co-I); Lynn Houck (PI) 2001-2005	NSF	\$663,821
Computer assisted tomography scanner (Co-I); William Hnat / Michael Voor (PIs) 2000-2002	NSF	\$500,000
Nutraceuticals and breast cancer (Co-I); A. F. Spatola (PI) 2001-2005	Congressional Priority Research	\$1,135,000
Structural roles of sphingolipids in human lens membranes (Co-I); M. C. Yappert (PI) 2001 - 2005	NIH	\$1,692,000
Mechanisms of SNAG dependent Transcriptional Repression (Co-I); H. Leighton Grimes (PI) 2001 - 2006	ACS	\$1,072,000
Mechanisms of SNAG dependent transcriptional repression (Co-I); H. Leighton Grimes (PI) 2001 - 2006	NIH	\$1,075,000
Molecular adaptation of the skeletal muscle calcium pump in the Wood Frog (Co-I); William Dean (PI) 1999 – 2003	NSF	\$959,383
Mechanisms of neutrophil activation (Co-I); Kenneth R. McLeish (PI) 2000-2005	NIH	\$1,620,000
Aldose reductase in vascular smooth muscle growth (Co-I); Si-Qi Liu (PI) 2000-2005	NIH	\$1,440,000
Institute for Molecular Diversity and Drug Design: Infrastructural Enhancement (Co-I); A. F. Spatola (PI ) 2001 - 2003	NSF EPSCoR	\$1,000,000
<b>Dr. Zhao-Hui (Joe) Song</b>		
Structure and function of CB2 cannabinoid receptor, DA11551 (PI) 09/30/98 – 09/30/03	NIH	\$507,304
Cannabinoid receptors-potential targets for novel antiglaucoma drugs (PI) 06/01/01 – 06/30/06	NIH	\$1,260,000

	<u>Agency</u>	<u>Budget Requested</u>
<b>Dr. J. Christopher States</b>		
DNA repair gene induction and genotoxicity of mixtures (PI) 12/00 – 11/05	NIEHS	\$875,000
Biomarkers of maternal and fetal tobacco smoke exposure (Co-I); Steven R. Myers (PI) 04/01/01 – 03/31/04	Phillip Morris External Research Program	\$2,537,671
<b>Dr. Leonard C. Waite</b>		
Molecular mechanisms of bone targeted estrogens (Co-I); William M. Pierce, Jr. (PI) 07/01/01 – 06/30/06	NIH	\$1,800,000

## Research Grants and Contracts in Force (salaried faculty)

	<u>Agency</u>	<u>Project Award</u>
<b>Dr. Frederick W. Benz</b>		
Acute acrylonitrile intoxication: Antidotal assessment (PI) 09/01/99 – 08/31/00	NIEHS	\$35,483
<b>Dr. Laurence A. Carr</b>		
An immunological role for brain dopamine systems (PI) 09/01/98-03/01/00	SOM Research Committee	\$7,920
<b>Dr. Theresa S. Chen</b>		
Acute acrylonitrile intoxication: Antidotal assessment (Co-I); F.W. Benz (PI) 09/01/98 – 08/31/00	NIEHS	\$35,483
<b>Dr. Paul N. Epstein</b>		
Antioxidant transgenes in diabetic cardiomyopathy (PI) 08/01/99 – 07/30/02	NIH	\$692,139
Acetaldehyde transgenes alter alcoholic cardiomyopathy (PI) 07/01/99 – 06/30/02	AHA	\$164,000
$\beta$ -cell antioxidant transgenes in diabetes and transplantation (PI) 09/01/00 – 08/31/04	NIH	\$706,000
Reducing diabetic cardiomyopathy by increasing glycolysis (PI) 09/30/00 – 09/29/04	NHLBI	\$847,800
<b>Dr. David Gozal</b>		
Neurocognitive function in snoring children (PI) 10/01/99 – 09/30/03	NHLBI	\$1,000,000
Sleep episodic hypoxia and memory deficit in aging rats: Protection by platelet-activating factor antagonists (PI) 01/00 – 12/02	AHA	\$214,500
Episodic hypoxia, Rem sleep deprivation, and hippocampal function (PI) 10/01/00 – 09/30/04	NHLBI	\$900,000

	<u>Agency</u>	<u>Project Award</u>
<b>Dr. David Gozal (cont.)</b>		
Proteomic analysis of hippocampal hypoxic vulnerability (Co-I); Jon B. Klein (PI) 10/01/00 – 09/30/04	NHLBI	\$700,000
Project on sleep disorders in children at risk for developmental problems (PI) 01/01/01 – 12/31/01	Department of Education	\$921,000
<b>Dr. Evelyne Gozal</b>		
Signaling pathways in neuronal susceptibility to hypoxia (PI) 10/01/00 – 09/30/04	Project 1, COBRE NIH	\$895,786
Proteomic analysis of hippocampal hypoxic vulnerability (Co-I); Jon B. Klein (PI) 10/01/00 – 09/30/04	NHLBI	\$700,000
<b>Dr. David W. Hein</b>		
Pharmacogenetics of drug and carcinogen metabolism (PI) 09/01/97 – 06/30/02	NCI	\$1,859,936
Metabolic Basis of Sulfonamide Toxicity in AIDS patients (P.I. on subproject) 09/01/97 – 05/31/01	NIH-Subcontract from Wayne State	\$768,169
Pharmacogenetics of drug and carcinogen metabolism (minority supplement) (PI) 12/01/00 – 06/30/02	NCI	\$16,183
<b>Dr. Harrell E. Hurst</b>		
N-(carboxymethyl)valine hemoglobin adduct: A marker for advanced glycosylation end product formation in diabetes (PI) 06/05/00 – 08/11/00	SOM 2000 Summer Res. Scholarship Program	\$3,256
Ethyl carbamate analysis in sugar cane distillate (PI) 07/07/98 – 06/30/01	Industrias Muller De Bebidas LTDA, Brazil	\$10,675

	<u>Agency</u>	<u>Project Award</u>
<b>Dr. Y. James Kang</b>		
Effect of catalase on adriamycin cardiotoxicity (PI) 08/01/95-09/30/00	NCI	\$507,500
Suppression of cardiac ischemia-reperfusion injury by overexpression of metallothionein (PI) 01/01/97-12/31/00	AHA	\$300,000
Metallothionein and adriamycin cardiotoxicity (PI) 04/01/99 – 03/31/02	NHLBI	\$623,000
Metallothionein and adriamycin cardiomyopathy (PI) 04/01/99 – 03/31/01	Jewish Hospital Foundation	\$50,000
<b>Dr. Glenn McGregor</b>		
Mechanisms of mutagenic processing of DNA damage, CA 73984 (PI) 08/01/97 – 07/31/02	NCI	\$350,000
<b>Dr. Steven R. Myers</b>		
In utero and neonatal exposure to environmental tobacco smoke and its effects on pulmonary development, lung function, and respiratory illness in the first year of life (Co-I); George Rodgers (PI) 1/1/95 – 12/31/00	Alliant Community Trust	\$203,980
Hewlett-Packard capillary electrophoresis/mass spectrometer (PI) 08/01/99 – 07/31/00	WHAS Crusade for Children	\$100,000
<b>Dr. Donald E. Nerland</b>		
Acute acrylonitrile intoxication: Antidotal assessment (Co-I); F.W. Benz (PI) 09/01/99-08/31/00	NIEHS	\$35,483
<b>Dr. William M. Pierce, Jr.</b>		
Proteomic analysis of hippocampal hypoxic vulnerability (Co-I); Jon B. Klein (PI) 2000-2004	NIH	\$1,000,800

	<u>Agency</u>	<u>Project Award</u>
<b>Dr. William M. Pierce, Jr. (cont.)</b>		
Central nervous system injury and repair (Co-I); (Program Director: Scott Whittemore, Project Director: E. Gozal) 2000-2004	NIH/COBRE	\$895,796
Regulation of neutrophil activation (Collaborator); Kenneth McLeish (PI) 1999-2002	VA Merit Review	\$407,000
Blood Lead Monitoring (Lab Director) 01/01/00 – 12/31/00	Analytical chemistry service for local and regional medical practitioners	\$32,837
Estrogens: Bone blood flow and bone Mechanical properties (Collaborator); John Fleming (PI) 1999 – 2001	NIH	\$50,000
P450 Metabolites of Arachidonic acid and DOCA salt hypertension (Co-I); Ayotunde Adeagbo (PI) 1999-2000	AHA Ohio Valley	\$75,000
Regulatory kinase signal transduction pathways in human neutrophils (Co-I); Kenneth R. McLeish (PI) 2000-2002	AHA – Ohio Valley	\$89,300
Toxicity and detoxification of 4-hydroxyalkenals in heart (Co-I); Aruni Bhatnagar (PI) 2000-2004	NIH	\$1,220,000
Transcriptional and posttranscriptional regulation of zfhep activity (Co-I); Douglas Darling (PI) 2000-2001	UofL School of Medicine	\$14,250
P450 metabolites of arachidonic acid and DOCA salt hypertension (Co-I); Ayotunde Adeagbo (PI) 1999-2000	UofL School of Medicine	\$15,000
<b>Dr. Peter P. Rowell</b>		
Functional activity of mesolimbic nicotinic receptors (PI) 9/1/99 – 6/30/02	NIH	\$299,508



	<u>Agency</u>	<u>Project Award</u>
<b>Dr. Peter P. Rowell (cont.)</b>		
Effect of nicotine on mesolimbic nicotinic receptor activation and desensitization (PI) 07/01/99 – 06/30/00	Kentucky Tobacco and Health Research Institute	\$77,943
Cholinergic influences on corticothalamic transmission (Co-I); A.R. Caggiula (PI) 10/01/00 – 09/30/05	NIH	\$875,000
<b>Dr. Zhao-Hui (Joe) Song</b>		
Structure and function of CB2 cannabinoid receptor (PI) 09/30/98 – 09/30/03	NIH	\$507,304
<b>Dr. J. Christopher States</b>		
DNA damage by bioactivated xenobiotics (PI) 03/97 – 07/01	NIEHS	\$862,845

## **IX. Teaching**

### **School of Medicine**

The Department team-taught the Medical Pharmacology course to second year medical students. Dr. Mike Williams served as course director. In addition, Dr. Laurence Carr served as co-director of the interdisciplinary Clinical Neuroscience course. Individual faculty contributions are identified in the Appendix.

### **School of Dentistry**

The Department team-taught the Dental Pharmacology and Therapeutics course to second year dental students. Dr. Leonard Waite served as course director. Individual faculty contributions are identified in the Appendix.

The Department team-taught a Pharmacology course to second year students in the Dental Hygiene Program. Dr. Leonard Waite served as course director. Individual faculty contributions are identified in the Appendix.

### **School of Nursing**

The Department team-taught a Basic Pharmacology for Nursing course to second year nursing students. The course is also cross-listed as Biology 390 and is taken by other undergraduate students. Dr. William Pierce served as course director. Individual faculty contributions are identified in the Appendix.

The Department team-taught an Advanced Pharmacology course to graduate nursing students. Dr. Leonard Waite served as course director. Individual faculty contributions are identified in the Appendix.

### **Graduate School**

The Department team-taught several courses for graduate students. The individual courses and course directors were as follows:

Principles of Drug Action (Dr. Frederick Benz)  
Research Methods (Dr. Chris States and Dr. Joe Song)  
Pharmacology Seminar (Dr. Donald Nerland)  
Introduction to Environmental Health (Dr. Steve Myers)  
Frameworks in Environmental Science and Technology (Dr. Steve Myers)

Individual faculty contributions to these courses are identified in the Appendix.

## **X. Service**

Faculty provided service to the Department, the School of Medicine, the University of Louisville, the profession, the nation, and the community in many ways. Individual faculty service activities are identified in the Appendix.

## **XI. Honors and Awards**

### *Graduate Students*

**Laila El-Sherif** received the first place award in graduate student competition at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics-Division of Toxicology.

**Scot Payne** received the 2000 KC Huang Outstanding Graduate Student Award in the Department of Pharmacology and Toxicology and received a first place award for his presentation at Louisville Neuroscience Day.

**Norma Nangju** received the second place award for her research presentations at the annual meeting of the Ohio Valley Society of Toxicology.

**Xin Fu** received the third place award for her research presentation at the annual meeting of the Ohio Valley Society of Toxicology, and honorable mention for her research presentation at Research!Louisville and received a travel award to attend the annual meeting of the American Society for Pharmacology and Experimental Therapeutics.

### *Faculty*

**Glenn McGregor** and **James Kang** received second place awards and **David Hein** received a third place award for research presentations at the annual Research!Louisville meeting.

**Evelyne Gozal** was promoted to a tenure track.

**Calvin Lang** and **Thom Zimmerman** retired and were appointed professor emeritus.

**James Kang** was reappointed as University Scholar.

**Paul Epstein** was appointed as Carol B. McFerran Endowed Chair in Pediatric Diabetes Research.

**David Gozal** was a Heritage Foundation Visiting Scholar at the University of Calgary and the University of Alberta.

**Fred Benz** received a Certificate of Appreciation for Community Service from the University of Louisville.

**Peter Rowell** was the School of Medicine’s nominee for the 2001 President’s Distinguished Faculty Award for Outstanding Scholarship, Research, and Creative Activity.

**David Hein** was elected Councilor for the American Association for Medical School Pharmacology.

## **XII. Standing Committees**

### Graduate Program Committee

Dr. William Pierce (Chair)  
Dr. Chris States (2002)  
Dr. Len Waite (2001)  
Dr. Peter Rowell (2000)  
Scot Payne (student representative)

### PBSI/Grievance Committee

Dr. Peter Rowell (Chair)  
Dr. Don Nerland (2002)  
Dr. Harrell Hurst (2001)  
Dr. Mike Williams (2000)

### Teaching Evaluation Committee

Dr. Larry Carr (Chair)  
Dr. Len Waite (2002)  
Dr. Fred Benz (2001)  
Dr. Mike Williams (2000)

### Seminar Committee

Dr. Don Nerland (Chair)  
Dr. Fred Benz (2002)  
Dr. Steve Myers (2001)  
Dr. Theresa Chen (2000)

### Core Laboratories/Research Development Committee

Dr. William Pierce (Chair)  
Dr. Chris States (2002)  
Dr. Theresa Chen (2001)  
Dr. Steve Myers (2000)

### Ad hoc Technology Committee

Dr. Harrell Hurst (Chair)  
Dr. Fred Benz